Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Takeda Pharmaceutical Co ( (JP:4502) ).
Takeda has decided to discontinue the development of its drug soticlestat (TAK-935) following unsuccessful Phase 3 trials for treating Dravet syndrome and Lennox-Gastaut syndrome. Despite the financial write-off of JPY 21.5 billion in intangible assets, the company expects the decision to have minimal impact on its financial results for the fiscal year ending March 31, 2025.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Co is a global pharmaceutical company focusing on various therapeutic areas, including neuroscience, gastroenterology, and oncology. It is known for developing innovative medicines and has a significant presence in both Japan and international markets.
YTD Price Performance: -2.61%
Average Trading Volume: 17,247
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $42.73B
See more data about 4502 stock on TipRanks’ Stock Analysis page.
